Evidence map›Paper›PMID 42304109›Full record

ArticleChemMedChem2026

Development of a Highly Effective Bifunctional Ligand 2E-C-NETA for Targeted Lu-177 Therapy: Synthesis, Radiolabeling, In Vitro Stability, and In Vivo Biodistribution.

Yenwei Chen, Yeseul Lee, Chi Soo Kang, Siyuan Ren, Yu Chen, Haixing Wang, Nilantha Bandara, Buck E Rogers, Hyun-Soon Chong

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in ChemMedChem, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Yenwei ChenDepartment of Chemistry, Illinois Institute of Technology, Chicago, Illinois, USA.
Yeseul LeeDepartment of Chemistry, Illinois Institute of Technology, Chicago, Illinois, USA.
Chi Soo KangDepartment of Chemistry, Illinois Institute of Technology, Chicago, Illinois, USA.
Siyuan RenDepartment of Chemistry, Illinois Institute of Technology, Chicago, Illinois, USA.
Yu ChenDepartment of Chemistry, Illinois Institute of Technology, Chicago, Illinois, USA.
Haixing WangDepartment of Chemistry, Illinois Institute of Technology, Chicago, Illinois, USA.
Nilantha BandaraDepartment of Radiation Oncology, Washington University, Saint Louis, Missouri, USA.
Buck E RogersDepartment of Radiation Oncology, Washington University, Saint Louis, Missouri, USA.
Hyun-Soon ChongDepartment of Chemistry, Illinois Institute of Technology, Chicago, Illinois, USA.ORCID 0000-0003-0299-7601

Funding

New Bifunctional Ligands for RadioimmunotherapyR01CA112503 · NCI · ILLINOIS INSTITUTE OF TECHNOLOGY · PI CHONG, HYUN-SOON · 2006 to 2017
$2.0M
NIH HHS R01CA112503
6 · The paper itself

Abstract

Lutetium-177 is a β-particle-emitting radionuclide widely used in targeted radionuclide therapy (TRT). The recent FDA approvals of

Indexed as

Antineoplastic AgentsChelating AgentsLutetiumRadioisotopesRadiopharmaceuticalsAnimalsCell Line, TumorFemaleHumansLigandsMiceMice, NudeTissue DistributionAntineoplastic AgentsChelating AgentsLigandsLutetiumLutetium-177RadioisotopesRadiopharmaceuticals177Lubifunctional chelatortargeted radionuclide therapy

Identifiers

PMID42304109
PMCPMC13272280

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.